Literature DB >> 6862593

Aggregation of equine platelets by PAF (platelet-activating factor).

C M Suquet, R W Leid.   

Abstract

Platelet-activating factor (PAF), a lipid released as a result of immediate allergic reactions from basophils and mast cells as well as by a variety of other cell types and stimuli, is one of the most potent platelet agonists and hypotensive agents known. Equine platelets stimulated over a wide range of PAF concentrations aggregated in a time- and dose-dependent manner. Maximum aggregation was observed at concentrations of PAF as low as 3.58 x 10(-14) M with platelet-rich plasma (PRP) and 3.58 x 10(-16) M with washed platelets. Furthermore, the aggregation observed did not appear to be breed-dependent. Finally, the platelet arachidonate pathway appeared to play no role in PAF-induced aggregation as exogenous arachidonate did not enhance the reaction, nor were equine platelets pretreated with 38 microM aspirin inhibited in their response to PAF. This level of aspirin totally inhibited the equine platelet aggregation response to arachidonate.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6862593     DOI: 10.1007/bf00917823

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  20 in total

Review 1.  Platelet-activating factor.

Authors:  J Benveniste; J Camussi; J Polonsky
Journal:  Monogr Allergy       Date:  1977

2.  Platelet-activating factor, a new mediator of anaphylaxis and immune complex deposition from rabbit and human basophils.

Authors:  J Benveniste
Journal:  Nature       Date:  1974-06-07       Impact factor: 49.962

3.  Antihypertensive activity of an alkyl ether analog of phosphatidylcholine.

Authors:  M L Blank; F Snyder; L W Byers; B Brooks; E E Muirhead
Journal:  Biochem Biophys Res Commun       Date:  1979-10-29       Impact factor: 3.575

4.  Thromboxane A2 generation by the larval cestode, Taenia taeniaeformis.

Authors:  R W Leid; L A McConnell
Journal:  Clin Immunol Immunopathol       Date:  1983-07

5.  One, two, three or more pathways for platelet aggregation.

Authors:  B B Vargaftig; M Chignard; J P Le Couedic; J Benveniste
Journal:  Acta Med Scand Suppl       Date:  1980

6.  Novel effects of 1-O-hexadecyl-2-acyl-sn-glycero-3-phosphorycholine mediators on human leukocyte function: delineation of the specific roles of the acyl substituents.

Authors:  E J Goetzl; C K Derian; A I Tauber; F H Valone
Journal:  Biochem Biophys Res Commun       Date:  1980-06-16       Impact factor: 3.575

7.  Immunity to the metacestode of Taenia taeniaeformis in the laboratory rat.

Authors:  R W Leid
Journal:  Am J Trop Med Hyg       Date:  1977-11       Impact factor: 2.345

8.  Platelet-activating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators).

Authors:  C A Demopoulos; R N Pinckard; D J Hanahan
Journal:  J Biol Chem       Date:  1979-10-10       Impact factor: 5.157

9.  A specific acetylhydrolase for 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (a hypotensive and platelet-activating lipid).

Authors:  M L Blank; T Lee; V Fitzgerald; F Snyder
Journal:  J Biol Chem       Date:  1981-01-10       Impact factor: 5.157

10.  Release of vasoactive amines from rabbit platelets induced by sensitized mononuclear leukocytes and antigen.

Authors:  P M Henson
Journal:  J Exp Med       Date:  1970-02       Impact factor: 14.307

View more
  1 in total

1.  The effect of intravenous administration of WEB 2086 on PAF-induced platelet aggregation in healthy Friesian calves.

Authors:  M B Bastos da Silva; P Gustin; F Herion; R Raskinet; J L David; T Gougnard; G Plomteux; D Desmecht; P Lekeux
Journal:  Vet Res Commun       Date:  1997-10       Impact factor: 2.459

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.